secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001213900-25-055334
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada appoints Dr. Raj S. Pruthi as CMO-Urology for NDV-01 NMIBC program
--------------------------------------------------------------------------

- Dr. Raj S. Pruthi appointed Chief Medical Officer-Urology effective June 17, 2025.
- He will lead development of NDV-01, a gemcitabine/docetaxel sustained release formulation for NMIBC.
- Company presented positive Phase 2 data at AUA 2025; Phase 3 trial expected to begin H1 2026.
- Dr. Pruthi brings over 25 years experience in urologic oncology, including roles at enGene and J&J.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025055334/0001213900-25-055334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025055334/ea0246111-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-055334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer